Effects of aprptinin on coagulation and fibrinolysis enzymes

Fibrinolysis and Proteolysis

Volumn 11, Issue 4, 1997, Pages 209-214

  Christensen, U ^a   Schiodt J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ALPHA 2 ANTIPLASMIN; APROTININ; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; PLASMIN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTICLE; BLEEDING; CARDIOVASCULAR SURGERY; CONCENTRATION RESPONSE; DRUG EFFECT; ENZYME ACTIVE SITE; ENZYME KINETICS; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; STEADY STATE; SURGICAL PATIENT;

EID: 0030680968     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80052-5     Document Type: Article

References (33)

1. Royston D. High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vase Anesth 1992; 6: 76-100.
2. Dietrich W, Barankay A, Hahnel C, Richter JA. High-dose aprotinin in cardiac surgery: three years' experience in 1784 patients. J Cardiothorac Vase Anesth 1992; 6: 324-327.
3. Cosgrove DM, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization. Ann Thorac Surg 1992; 54: 1031-1038.
4. Bidstrup BP, Harrison J, Royston D, Taylor KM, Treasure T. Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 1993; 55: 971-976.
5. Bidstrup BP, Underwood SR, Sapsford RN. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg 1993; 105: 147-153.
6. Levy JH, Pifarre R, Schaff HV, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing coronary artery bypass grafting. Circulation 1995; 92: 2236-2244.
7. Kraut H, Frey EK, Werle E. Über die inactivierung des Kallikreins. Hoppe-Seyler's Z Physiol Chem 1930; 192: 1-21.
8. Kunitz M, Northrop JH. Isolation from beef pancreas of crystalline trypsinogen, trypsin, trypsin inhibitor and an inhibitor-trypsin compound. J Gen Physiol 1936; 19: 991-1007.
9. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallicrein inhibitor from bovine organs. ArzneimForsch/Drug Res 1983; 33: 479-494.
10. Hardy J-F, Desroches J, Belisle S, Perrault J, Carrier M, Robitaille D. Low- dose aprotinin infusion is not clinically useful to reduce bleeding and transfusion of homologous blood products in high-risk cardiac surgical patients. Can J Anaesth 1993; 40: 625-631.
11. Wiman B. On the reaction of plasmin or plasmin-streptokinase complex with aprotinin or
12. Petersen LC, Clemmensen I. Kinetics of plasmin inhibition in the presence of synthetic tripeptide substrate. Biochem J 1981; 199: 121-127.
13. Christensen U, Ipsen H-H. Steady-state kinetics of plasmin and trypsin-catalysed hydrolysis of a number of tripeptide-pnitroanilides. Biochim Biophys Acta 1979; 569: 177-183.
14. Christensen U. pH effects in plasmin-catalysed hydrolysis of a-N-benzoyl-L-arginine compounds. Biochim Biophys Acta 1975; 397: 459-467.
15. Christensen U, Bangert K, Thorsen S. Reaction of a2~anu'plasmin and plasmin. Stopped-flow fluorescence kinetics. FEES Lett 1996; 387: 58-62.
16. Ipsen H-H, Christensen U. Kinetic studies of urokinase-catalysed hydrolysis of 5-oxo-L-prolyl-l-arginine 4-nitroanilide. Biochim Biophys Acta 1980; 613: 476-481.
17. Lottenberg R, Christensen U, Jackson CM, Coleman PL. Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates. MethEnzymol 1981; 80: 341-361.
18. Lottenberg R, Hall JA, Pautler E, Zupan A, Christensen U, Jackson CM. The action of Factor Xa on peptide p-nitroanilide substrates: substrate selectivity and examination of hydrolysis with different reaction conditions. Biochim Biophys Acta 1986; 874: 326-336.
19. Stone SR, Hofsteenge J. Specificity of activated Protein C. BiochemJ 1985; 230: 497-502.
20. Pedersen AH, Nordfang O, Noms F, et al. Recombinant human extrinsic pathway inhibitor. J Biol Chem 1990; 265: 16786-16793.
21. Sidelmann J, Jespersen J, Gram J. Measurements of plasminogen activator activity and plasma-coagulum lysis measured by use of optimized fibrin gel structure preformed in microtiter plates. Clin Chem 1995; 41: 979-85.
22. Christensen U, Sottrup-Jensen L. Mechanism of a2-macroglobulinproteinase interactions. Studies with trypsin and plasmin. Biochemistry 1984; 23: 6619-6626.
23. Aasen AO, Gallimore MJ, Lilleaasen P, Lyngaas K, Larsbraaten M, Amundsen E. Changes in antiplasmin and plasmin activities during extreme hemodilution and open heart surgery in dogs. EurSurg Res 1979; 11: 145-153.
24. Büller HR, Henny Ch P, Ritzen M, Kahlé LH, ten Cate JW. Intraoperative antithrombin III, plasminogen and a2-antiplasmin behaviour. Thromb Haemos 1981; 46: 300.
25. Coleman PL, Patel PD, Cwikel BJ, Rafferty UM, Sznycer-Laszuk R, Gelehrter TD. Characterization of the dexamethasoneinduced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem 1986; 261: 4352-4357.
26. Hekman CM, Loskutoff DJ. Kinetic analysis of the interaction between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator. Arch Biochem Biophys 1988; 262: 199-210.
27. Chmielewska J, Rânby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-436.
28. Juhan-Vague I, Moerman B, DeCock F, Aillaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523- 530.
29. Pauling L. Chemical achievements and hope for the future. Amer Scientist, 1948; 36: 51- 58.
30. Christensen U. Urokinase-catalysed plasminogen activation. Effects of ligands binding to the AH-site of plasminogen. Biochim. Biophys Acta 1988; 957; 258-265.
31. Stieff T, Radtke KP, Heimburger N. Evidence for identity of PCI and plasminogen activator inhibitor 3. Biol Chem Hoppe-Seyler, 1987; 368: 1427-1433.
32. 1-antitrypsin. J Biol Chem 1988; 263: 11613-11616.
33. Feinman RD. Kinetics and mechanism of the antithrombinprotease reaction. In: Collen D, Wiman B, Verstraete M, eds. The physiological inhibitors of blood coagulation and fibrinolysis. Amsterdam: Elsevier/North-Holland Biomédical Press, 1979; 55-66.